Researchers posit that the development of multi-antigen targeted antibodies, in combination with anti-PD-1/PD-L1 antibodies, as well as the targeting of co-stimulatory/inhibitory receptors, may further enhance the efficacy of anti-tumor therapy. The gene discussed is PDCD1; the disease is neoplasm.